© 1994 Oxford University Press
OTHER |
Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the 
-galactosidase A gene
1Departments of Human Genetics, Mount Sinai School of Medicine Fifth Avenue and 100th Street, New York, NY 10029, USA 2Departments of Pediatrics, Mount Sinai School of Medicine Fifth Avenue and 100th Street, New York, NY 10029, USA 3Department of Pediatrics, Dalhousie University Halifax, Nova Scotia, Canada
*To whom correspondence should be addressed
Received May 25, 1994; Revised August 2, 1994; Accepted August 2, 1994
Fabry disease, an X-linked inborn error of glycosphingolipid catabolism, results from mutations in the 
-galactosidase A gene at Xq22.1. To determine the nature and frequency of the molecular lesions causing the classical and milder variant Fabry phenotypes, and for precise carrier detection in Fabry families, the -galactosidase A coding and flanking intronic sequences from 23 unrelated Fabry hemizygotes were analyzed. In patients with the classic phenotype, 16 new missense and nonsense mutations and four small exonic gene rearrangements were identified: C52S, C56F, E59K, L89R, R100K, R112H, L131P, A143P, G144V, C172Y, D244N, N272K, A288D, W81X, Q99X, Q157X, R301X, 25del1, 333del18, 358del6, and 1020del1. The R112H mutation at a CpG dinucleotide resulted in residual activity and a mild variant phenotype while the R112C lesion caused the classic disease manifestations, defining a genotype/phenotype correlation for sense and antisense mutations at the same CpG dinucleotide. In addition, two complex rearrangements, each involving two mutational events, occurred in classic hemizygotes. Both rearrangements resulted in missense mutations that did not change the reading frame. Notably, three of the deletions occurred within 11 codons in exon 2, thereby defining a ‘hot-spot’ for deletions. These studies revealed that most mutations in the -galactosidase A gene causing Fabry disease were private, that codons 111–122 defined a deletion hot-spot, and that different substitutions of the same codon resulted in markedly different disease phenotypes.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Ortiz, B. Cianciaruso, M. Cizmarik, D. P. Germain, R. Mignani, J. P. Oliveira, J. Villalobos, B. Vujkovac, S. Waldek, C. Wanner, et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry Nephrol. Dial. Transplant., October 21, 2009; (2009) gfp554v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Lin, K.-W. Chong, J.-H. Hsu, H.-C. Yu, C.-C. Shih, C.-H. Huang, S.-J. Lin, C.-H. Chen, C.-C. Chiang, H.-J. Ho, et al. High Incidence of the Cardiac Variant of Fabry Disease Revealed by Newborn Screening in the Taiwan Chinese Population Circ Cardiovasc Genet, October 1, 2009; 2(5): 450 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. West, K. Nicholls, A. Mehta, J. T.R. Clarke, R. Steiner, M. Beck, B. A. Barshop, W. Rhead, R. Mensah, M. Ries, et al. Agalsidase Alfa and Kidney Dysfunction in Fabry Disease J. Am. Soc. Nephrol., May 1, 2009; 20(5): 1132 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Frustaci, C. Chimenti, R. Ricci, L. Natale, M. A. Russo, M. Pieroni, C. M. Eng, and R. J. Desnick Improvement in Cardiac Function in the Cardiac Variant of Fabry's Disease with Galactose-Infusion Therapy N. Engl. J. Med., July 5, 2001; 345(1): 25 - 32. [Full Text] [PDF]
|
|